No Data
No Data
ADRs End Higher; I-Mab Climbs 43%
ABL Bio Informuje O Licenčnej Zmluve K Platforme Podávania Liekov Do Mozgu Grabody-B so Spoločnosťou GSK Na Vývoj Nových Liekov Proti Neurodegeneratívnym Ochoreniam
I-Mab To Present At 24th Annual Needham Virtual Healthcare Conference; Webcast At 8:45 AM ET
I-Mab Positions for Growth With U.S. Focus and Innovative Cancer Treatments
12 Health Care Stocks Moving In Friday's After-Market Session
Needham Maintains I-Mab(IMAB.US) With Buy Rating, Maintains Target Price $4
Tom’s Jerry : IMAB feels very good.
Tom’s Jerry : Let me guess: are you a Chinese person in Los Angeles.
Jaguar8 OP Tom’s Jerry : No. I am not also in SoCal
XSL : Thank you, teacher, for the Share

Tom’s Jerry Jaguar8 OP : ok![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
View more comments...